Effect of MTHFR677C>T on plasma total homocysteine levels in renal graft recipients

被引:59
作者
Födinger, M
Wölfl, G
Fischer, G
Rasoul-Rockenschaub, S
Schmid, R
Hörl, WH
Sunder-Plassmann, G
机构
[1] Univ Vienna, Innere Med Klin 3, Klin Abt Nephrol & Dialyse, A-1090 Vienna, Austria
[2] Univ Vienna, Klin Inst Med & Chem Lab Diagnost, A-1090 Vienna, Austria
[3] Univ Vienna, Inst Med Stat, A-1090 Vienna, Austria
[4] Univ Vienna, Klin Blutgrp Serol & Transfus Med, A-1090 Vienna, Austria
[5] Univ Vienna, Chirurg Klin, Klin Abt Transplantat, A-1090 Vienna, Austria
关键词
hyperhomocysteinemia; transplantation; polymorphism; MTHFR; folate; vitamin B-12; cardiovascular disease;
D O I
10.1046/j.1523-1755.1999.0550031072.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Hyperhomocysteinemia is an established, independent risk factor for vascular disease morbidity and mortality. The 5,10-methylenetetrahydrofolate reductase (MTHFR) gene polymorphism C677T has been shown to result in increased total homocysteine concentrations on the basis of low folate levels caused by a decreased enzyme activity. The effect of this polymorphism on total homocysteine and folate plasma levels in renal transplant patients is unknown. Methods. We screened 636 kidney graft recipients for the presence of the MTHFR C677T gene polymorphism. The major determinants of total homocysteine and folate plasma concentrations of 63 patients, who were identified to be homozygous for this gene polymorphism compared with heterozygotes (N = 63), and patients with wild-type alleles (N = 63), who were matched for sex, age, glomerular filtration rate (GFR), and body mass index, were identified by analysis of covariance. The variables included sex, age, GFR, body mass index, time since transplantation, folate and vitamin B-12 levels, the use of azathioprine, and the MTHFR genotype. To investigate the impact of the kidney donor MTHFR genotype on total homocysteine and folate plasma concentrations, a similar model was applied in 111 kidney graft recipients with stable graft function, in whom the kidney donor C677T MTHFR gene polymorphism was determined. Results. The allele frequency of the C677T polymorphism in the MTHFR gene was 0.313 in the whole study population [wild-type (CC), 301; heterozygous (CT), 272; and homozygous mutant (TT), 63 patients, respectively] and showed no difference in the patient subgroups with various renal diseases. The MTHFR C677T gene polymorphism significantly influenced total homocysteine and folate plasma concentrations in renal transplant recipients (P = 0.0009 and P = 0.0002, respectively). Furthermore, a significant influence of the GFR (P = 0.0001), folate levels (P = 0.0001), age (P = 0.0001), body mass index (P = 0.0001), gender (P = 0.0005), and vitamin B-12 levels (P = 0.004) on total homocysteine concentrations was observed. The donor MTHFR gene polymorphism had no influence on total homocysteine and folate levels. Geometric mean total homocysteine levels in patients homozygous for the mutant MTHFR allele were 18.6 mu mol/liter compared with 14.6 mu mol/liter and 14.9 mu mol/liter in patients heterozygous for the MTHFR gene polymorphism and those with wild-type alleles (P < 0.05 for TT vs. CT and CC). Geometric mean folate levels were lower in CT and TT patients (11.2 and 10.2 nmol/liter) compared with CC patients (13.6 nmol/liter, P < 0.05 vs. CT and TT). Conclusions. This study demonstrates that homozygosity for the C677T polymorphism in the MTHFR gene significantly increases total homocysteine concentrations and lowers folate levels in kidney graft recipients, even in patients with excellent renal function (GFR more than median). These findings have important implications for risk evaluation and vitamin intervention therapy in these patients who carry an increased risk for the development of cardiovascular disease.
引用
收藏
页码:1072 / 1080
页数:9
相关论文
共 52 条
[1]   Treatment with high-dose folic acid effectively lowers plasma homocysteine concentration in cyclosporine-treated renal transplant recipients [J].
Arnadottir, M ;
Hultberg, B .
TRANSPLANTATION, 1997, 64 (07) :1087-1087
[2]   Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients [J].
Arnadottir, M ;
Hultberg, B ;
Vladov, V ;
NilssonEhle, P ;
Thysell, H .
TRANSPLANTATION, 1996, 61 (03) :509-512
[3]   COMPARISON OF FOLIC-ACID COENZYME DISTRIBUTION PATTERNS IN PATIENTS WITH METHYLENETETRAHYDROFOLATE REDUCTASE AND METHIONINE SYNTHETASE DEFICIENCIES [J].
BAUMGARTNER, ER ;
STOKSTAD, ELR ;
WICK, H ;
WATSON, JE ;
KUSANO, G .
PEDIATRIC RESEARCH, 1985, 19 (12) :1288-1292
[4]   NET UPTAKE OF PLASMA HOMOCYSTEINE BY THE RAT-KIDNEY IN-VIVO [J].
BOSTOM, A ;
BROSNAN, JT ;
HALL, B ;
NADEAU, MR ;
SELHUB, J .
ATHEROSCLEROSIS, 1995, 116 (01) :59-62
[5]   Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients [J].
Bostom, AG ;
Shemin, D ;
Lapane, KL ;
Nadeau, MR ;
Sutherland, P ;
Chan, J ;
Rozen, R ;
Yoburn, D ;
Jacques, PF ;
Selhub, J ;
Rosenberg, IH .
ATHEROSCLEROSIS, 1996, 123 (1-2) :193-202
[6]   High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients [J].
Bostom, AG ;
Shemin, D ;
Lapane, KL ;
Hume, AL ;
Yoburn, D ;
Nadeau, MR ;
Bendich, A ;
Selhub, J ;
Rosenberg, IH .
KIDNEY INTERNATIONAL, 1996, 49 (01) :147-152
[7]   Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients - A prospective study [J].
Bostom, AG ;
Shemin, D ;
Verhoef, P ;
Nadeau, MR ;
Jacques, PF ;
Selhub, J ;
Dworkin, L ;
Rosenberg, IH .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (11) :2554-2558
[8]   Treatment of hyperhomocysteinemia in renal transplant recipients - A randomized, placebo-controlled trial [J].
Bostom, AG ;
Gohh, RY ;
Beaulieu, AJ ;
Nadeau, MR ;
Hume, AL ;
Jacques, PF ;
Selhub, J ;
Rosenberg, IH .
ANNALS OF INTERNAL MEDICINE, 1997, 127 (12) :1089-1092
[9]   HYPERHOMOCYSTEINEMIA AND TRADITIONAL CARDIOVASCULAR-DISEASE RISK-FACTORS IN END-STAGE RENAL-DISEASE PATIENTS ON DIALYSIS - A CASE-CONTROL STUDY [J].
BOSTOM, AG ;
SHEMIN, D ;
LAPANE, KL ;
MILLER, JW ;
SUTHERLAND, P ;
NADEAU, M ;
SEYOUM, E ;
HARTMAN, W ;
PRIOR, R ;
WILSON, PWF ;
SELHUB, J .
ATHEROSCLEROSIS, 1995, 114 (01) :93-103
[10]   Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes [J].
Bostom, AG ;
Lathrop, L .
KIDNEY INTERNATIONAL, 1997, 52 (01) :10-20